Bleeding or bleeding risk with increased fibrinolysis as generalized (bleeding during surgery and postoperative prostate, hemorrhagic complications of fibrinolytic therapy) and local (uterine, gastrointestinal, nasal bleeding, post-operative bleeding, post-operative bleeding) bladder, tonsillectomy, cervical conization, tooth extraction in hemophilia patients). Hereditary angioneurotic edema.
Composition and form of release
Active ingredients: tranexamic acid (250 mg).
Trenax 250 is produced in tablet form.
It is an antihemorrhagic agent. It is an inhibitor of fibrinolysis. Specifically inhibits the activation of plasminogen (profibrinolysin), its transformation into plasmin (fibrinolysin). It has a systemic and local hemostatic effect in bleeding, which is associated with an increase in fibrinolysis (menorrhagia, platelet pathology). Also, tranexamic acid has an anti-allergic, anti-inflammatory effect by inhibiting the formation of kinins, other active peptides involved in reactions of this type.
Trenax 250 is used:
- with bleeding or the risk of bleeding due to increased fibrinolysis, as generalized (during operations, in the postoperative period, after childbirth, manual separation of the placenta, with chorionic detachment, bleeding during pregnancy, with malignant neoplasm of the pancreas or prostate glands, with hemophilia, hemorrhagic complications fibrinolytic therapy, with thrombocytopenic purpura, liver diseases, leukemia, after streptokinase therapy), and local bleeding (pulmonary, uterine, nasal, gastrointestinal, hematuria, after conization of the cervix for carcinoma, after prostatectomy, tooth extraction in individuals with hemorrhagic diathesis);
- with hereditary angioedema.
Trenax 250 is not used:
- if you are allergic to tranexamic acid;
- with intolerance to auxiliary components;
- with a history of thromboembolic diseases;
- with a high risk of thrombosis, thrombophlebitis;
- with macroscopic hematuria;
- with coagulopathy due to disseminated intravascular coagulation (diffuse intravascular coagulation) without fibrinolysis activation;
- with myocardial infarction;
- with subarachnoid hemorrhage;
- with a history of seizures;
- in case of violation of color vision;
- with severe kidney failure.
Application during pregnancy and lactation
There have been no strictly controlled clinical studies of the safety of tranexamic acid during pregnancy. No teratogenic or embryotoxic effects were found.
The drug is prescribed to pregnant women if the expected health benefits to the mother outweigh the risk to the fetus.
The drug is used in childbirth and cesarean section.
The active substance passes into breast milk in small amounts. If there is a need for treatment, the question of stopping breastfeeding is decided.
Method of administration and dosage
Trenax 250 is used internally.
The dosage regimen is selected individually depending on the clinical situation.
The standard dose is 15 mg / kg every 6-8 hours.
Symptoms: convulsions, nausea, orthostatic symptoms, dizziness, vomiting, arterial hypotension, headache, increased manifestations of adverse reactions.
Treatment: the appointment of symptomatic therapy, forced diuresis, maintenance of the water-salt balance.
- Gastrointestinal disorders: nausea, heartburn, vomiting, diarrhea, discomfort in the intestines and stomach.
- Neurological disorders: convulsions, drowsiness, dizziness.
- Cardiovascular disorders: arterial hypotension, orthostatic hypotension, chest pain, tachycardia, thromboembolism, pulmonary embolism, deep vein thrombosis, cerebral vessels.
- Urinary disorders: acute necrosis of the renal cortex.
- Ophthalmic disorders: chromatopsia, impairment, blurred vision.
- General disorders: weakness, manifestations of hypersensitivity (including anaphylaxis, allergic dermatitis, skin rashes, itching, urticaria).
Storage conditions and periods
Store Trenax 250 for no more than two years at temperatures up to +25 ° C.